SB-509

Drug Name: SB-509
Company: Sangamo Biosciences
Location: US-California
Website: http://www.sangamo.com
Drug Type: Gene Therapy
Conditions: ALS
Mechanism Type: Neuroprotection
Mechanism: SB-509 is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A).
U.S. Status for ALS: Discontinued

References:
[1] Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS). ClinicalTrials.gov, 30 Oct 2012. Accessed 11 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT00748501.

Last updated March 11th, 2016

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail